title: Central nervous system toxicities of chemotherapeutic agents.
abstract: Although there has been a significant progress in the recognition and management of the most common chemotherapy side effects, there is limited data on CNS toxicities. Since CNS toxicities can cause significant morbidity and delay or interruption of potentially effective therapies, there is a need for better understanding, early detection, prompt discontinuation of the offending drug, and use of antidotes when available. This review describes neurological toxicities from some of the commonly used chemotherapy agents.
authors.affiliation: Division of Hematology Oncology, University of California, 10945 LeConte Avenue, Suite 2333, Los Angeles, CA 90095-7059, USA.
authors.forename: Parvin F
authors.initials: PF
authors.lastname: Peddi
authors.forename: Srinivas
authors.initials: S
authors.lastname: Peddi
authors.forename: Edgardo S
authors.initials: ES
authors.lastname: Santos
authors.forename: Daniel
authors.initials: D
authors.lastname: Morgensztern
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000139:chemically induced*; D002945:Cisplatin / Q000009:adverse effects; D003561:Cytarabine / Q000009:adverse effects; D005472:Fluorouracil / Q000009:adverse effects; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D020258:Neurotoxicity Syndromes / Q000209:etiology*; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced*; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives; D014750:Vincristine / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D003561:Cytarabine; D014750:Vincristine; D014740:Vidarabine; C024352:fludarabine; D002945:Cisplatin; D005472:Fluorouracil; D007069:Ifosfamide; D008727:Methotrexate
keywords: CNS; antidotes; chemotherapy; encephalopathy; posterior reversible encephalopathic syndrome